London, UK-based Ark Therapeutics says that the Marketing Authorization Application for Cerepro, its novel gene-based therapy for operable malignant glioma that was recently filed with the European Medicines Agency (EMEA), has cleared the validation stage. The MAA now commences formal review via the centralized procedure which is the standard route for all advanced therapies.
Cerepro was originally filed for marketing approval under exceptional circumstances in late 2005 and was reviewed by the EMEA with reliance on Phase II data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze